# OnCo record all-paediatric-ph-positive (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-paediatric-ph-positive/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-paediatric-ph-positive" ;
  schema:name "Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)"@en ;
  schema:alternateName "Ph+ ALL in children"@en, "BCR::ABL1-positive childhood ALL"@en, "Paediatric Ph-positive ALL"@en ;
  schema:description "Philadelphia chromosome-positive leukaemia carries the same faulty BCR::ABL1 gene as chronic myeloid leukaemia. Until 2000 most children with it needed a bone marrow transplant; adding the targeted pill imatinib to chemotherapy, and then dasatinib, means most are now cured without one."@en ;
  schema:url <https://onco.cc/cancers/all-paediatric-ph-positive/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Philadelphia_chromosome> ;
  schema:citation <https://en.wikipedia.org/wiki/Philadelphia_chromosome>, <https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/all-ph-like/>, <https://onco.cc/cancers/cml-chronic-phase/>, <https://onco.cc/cancers/all-paediatric-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/cd19/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> ;
  onco:pathways <https://onco.cc/pathways/bcr-abl1-signalling/> ;
  onco:terms <https://onco.cc/terms/philadelphia-chromosome/>, <https://onco.cc/terms/ph-positive-all/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/abl1-kinase-domain-mutations/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009/>, <https://onco.cc/key-papers/paper-esphall-imatinib-biondi-lancet-oncol-2012/>, <https://onco.cc/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/> ;
  onco:pipeline <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/>, <https://onco.cc/ideas/idea-transplant-free-ph-all/>, <https://onco.cc/trials/d-alba/>, <https://onco.cc/trials/phallcon/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:standardOfCare <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/terms/ph-positive-all/>, <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/> .